Статті в журналах з теми "BOCEPREVIR RESISTANCE"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся з топ-40 статей у журналах для дослідження на тему "BOCEPREVIR RESISTANCE".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Переглядайте статті в журналах для різних дисциплін та оформлюйте правильно вашу бібліографію.
Flint, Mike, Stanley Mullen, Anne M. Deatly, Wei Chen, Lynn Z. Miller, Robert Ralston, Colin Broom, Emilio A. Emini, and Anita Y. M. Howe. "Selection and Characterization of Hepatitis C Virus Replicons Dually Resistant to the Polymerase and Protease Inhibitors HCV-796 and Boceprevir (SCH 503034)." Antimicrobial Agents and Chemotherapy 53, no. 2 (October 20, 2008): 401–11. http://dx.doi.org/10.1128/aac.01081-08.
Повний текст джерелаAndonov, Anton, Kamran Kadkhoda, Carla Osiowy, and Kelly Kaita. "Pretreatment Resistance to Hepatitis C Virus Protease Inhibitors Boceprevir/Telaprevir in Hepatitis C Subgenotype 1A-Infected Patients from Manitoba." Canadian Journal of Gastroenterology 27, no. 7 (2013): 414–16. http://dx.doi.org/10.1155/2013/273856.
Повний текст джерелаBarnard, Richard J. O., John A. Howe, Robert A. Ogert, Stefan Zeuzem, Fred Poordad, Stuart C. Gordon, Robert Ralston, et al. "Analysis of boceprevir resistance associated amino acid variants (RAVs) in two phase 3 boceprevir clinical studies." Virology 444, no. 1-2 (September 2013): 329–36. http://dx.doi.org/10.1016/j.virol.2013.06.029.
Повний текст джерелаWelsch, Christoph, Sabine Schweizer, Tetsuro Shimakami, Francisco S. Domingues, Seungtaek Kim, Stanley M. Lemon, and Iris Antes. "Ketoamide Resistance and Hepatitis C Virus Fitness in Val55 Variants of the NS3 Serine Protease." Antimicrobial Agents and Chemotherapy 56, no. 4 (January 17, 2012): 1907–15. http://dx.doi.org/10.1128/aac.05184-11.
Повний текст джерелаSerre, Stéphanie B. N., Sanne B. Jensen, Lubna Ghanem, Daryl G. Humes, Santseharay Ramirez, Yi-Ping Li, Henrik Krarup, Jens Bukh, and Judith M. Gottwein. "Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants:In VitroSelection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle." Antimicrobial Agents and Chemotherapy 60, no. 6 (March 28, 2016): 3563–78. http://dx.doi.org/10.1128/aac.02929-15.
Повний текст джерелаTong, X., A. Arasappan, F. Bennett, R. Chase, B. Feld, Z. Guo, A. Hart, et al. "Preclinical Characterization of the Antiviral Activity of SCH 900518 (Narlaprevir), a Novel Mechanism-Based Inhibitor of Hepatitis C Virus NS3 Protease." Antimicrobial Agents and Chemotherapy 54, no. 6 (March 2, 2010): 2365–70. http://dx.doi.org/10.1128/aac.00135-10.
Повний текст джерелаJensen, Sanne B., Stéphanie B. N. Serre, Daryl G. Humes, Santseharay Ramirez, Yi-Ping Li, Jens Bukh, and Judith M. Gottwein. "Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance." Antimicrobial Agents and Chemotherapy 59, no. 12 (September 21, 2015): 7426–36. http://dx.doi.org/10.1128/aac.01953-15.
Повний текст джерелаNagpal, Neha, Sukriti Goyal, Divya Wahi, Ritu Jain, Salma Jamal, Aditi Singh, Preeti Rana, and Abhinav Grover. "Molecular principles behind Boceprevir resistance due to mutations in hepatitis C NS3/4A protease." Gene 570, no. 1 (October 2015): 115–21. http://dx.doi.org/10.1016/j.gene.2015.06.008.
Повний текст джерелаSusser, Simone, Christoph Welsch, Yalan Wang, Markus Zettler, Francisco S. Domingues, Ursula Karey, Eric Hughes, et al. "Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients." Hepatology 50, no. 6 (August 4, 2009): 1709–18. http://dx.doi.org/10.1002/hep.23192.
Повний текст джерелаBrass, Clifford A., Richard J. Barnard, John A. Howe, Robert A. Ogert, Robert Ralston, Navdeep Boparai, Margaret Burroughs, Vilma Sniukiene, Patricia Mendez, and Janice K. Albrecht. "Sustained Virologic Response and Boceprevir Resistance-Associated Variants Observed in Patients Infected With HCV Genotype 1A/1b When Treated With Boceprevir Plus Peginterferon Alfa-2B/Ribavirin." Gastroenterology 140, no. 5 (May 2011): S—942—S—943. http://dx.doi.org/10.1016/s0016-5085(11)63909-7.
Повний текст джерелаBrass, C., R. J. O. Barnard, J. A. Howe, R. A. Ogert, R. Ralston, N. Boparai, M. Burroughs, V. Sniukiene, P. Mendez, and J. Albrecht. "1194 SUSTAINED VIROLOGIC RESPONSE AND BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS OBSERVED IN PATIENTS INFECTED WITH HCV GENOTPYPE 1A/1B WHEN TREATED WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN." Journal of Hepatology 54 (March 2011): S471—S472. http://dx.doi.org/10.1016/s0168-8278(11)61196-3.
Повний текст джерелаStrahotin, Cristina Simona, and Michael Babich. "Hepatitis C Variability, Patterns of Resistance, and Impact on Therapy." Advances in Virology 2012 (2012): 1–10. http://dx.doi.org/10.1155/2012/267483.
Повний текст джерелаChae, Hee Bok, Seon Mee Park, and Sei Jin Youn. "Direct-Acting Antivirals for the Treatment of Chronic Hepatitis C: Open Issues and Future Perspectives." Scientific World Journal 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/704912.
Повний текст джерелаLópez-Labrador, F. Xavier, Andrés Moya, and Fernando Gonzàlez-Candelas. "Mapping Natural Polymorphisms of Hepatitis C virus NS3/4A Protease and Antiviral Resistance to Inhibitors in Worldwide Isolates." Antiviral Therapy 13, no. 4 (May 2008): 481–94. http://dx.doi.org/10.1177/135965350801300413.
Повний текст джерелаCuypers, Lize, Pieter Libin, Yoeri Schrooten, Kristof Theys, Velia Chiara Di Maio, Valeria Cento, Maja M. Lunar, et al. "Exploring resistance pathways for first-generation NS3/4A protease inhibitors boceprevir and telaprevir using Bayesian network learning." Infection, Genetics and Evolution 53 (September 2017): 15–23. http://dx.doi.org/10.1016/j.meegid.2017.05.007.
Повний текст джерелаSalam, Kazi Abdus, and Nobuyoshi Akimitsu. "Hepatitis C Virus NS3 Inhibitors: Current and Future Perspectives." BioMed Research International 2013 (2013): 1–9. http://dx.doi.org/10.1155/2013/467869.
Повний текст джерелаMacartney, Malcolm J., Dianne Irish, Simon H. Bridge, Ana Garcia-Diaz, Clare L. Booth, Adele L. McCormick, Wendy Labbett, et al. "Telaprevir or boceprevir based therapy for chronic hepatitis C infection: Development of resistance-associated variants in treatment failure." Antiviral Research 105 (May 2014): 112–17. http://dx.doi.org/10.1016/j.antiviral.2014.02.019.
Повний текст джерелаTornai, István. "A hepatitis C-vírus-bázispolimorfizmus jelentősége a kezelésben." Orvosi Hetilap 156, no. 21 (May 2015): 849–54. http://dx.doi.org/10.1556/650.2015.30180.
Повний текст джерелаSumma, Vincenzo, Steven W. Ludmerer, John A. McCauley, Christine Fandozzi, Christine Burlein, Giuliano Claudio, Paul J. Coleman, et al. "MK-5172, a Selective Inhibitor of Hepatitis C Virus NS3/4a Protease with Broad Activity across Genotypes and Resistant Variants." Antimicrobial Agents and Chemotherapy 56, no. 8 (May 21, 2012): 4161–67. http://dx.doi.org/10.1128/aac.00324-12.
Повний текст джерелаBehmard, Esmaeil, and Ebrahim Barzegari. "Insights into resistance mechanism of hepatitis C virus nonstructural 3/4A protease mutant to boceprevir using umbrella sampling simulation study." Journal of Biomolecular Structure and Dynamics 38, no. 7 (May 31, 2019): 1938–45. http://dx.doi.org/10.1080/07391102.2019.1621212.
Повний текст джерелаSchaefer, Daniel, and Xinlai Cheng. "Recent Advances in Covalent Drug Discovery." Pharmaceuticals 16, no. 5 (April 28, 2023): 663. http://dx.doi.org/10.3390/ph16050663.
Повний текст джерелаSusser, Simone, Johannes Vermehren, Nicole Forestier, Martin Walter Welker, Natalia Grigorian, Caterina Füller, Dany Perner, Stefan Zeuzem, and Christoph Sarrazin. "Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir." Journal of Clinical Virology 52, no. 4 (December 2011): 321–27. http://dx.doi.org/10.1016/j.jcv.2011.08.015.
Повний текст джерелаBlack, S., P. McMonagle, R. Chase, S. Curry, R. J. O. Barnard, D. J. Hazuda, A. Y. Howe, J. A. Howe, and R. A. Ogert. "1198 HCV NS3/4A PROTEASE RESISTANCE-ASSOCIATED VARIANTS (RAVS) IDENTIFIED IN GENOTYPE 1A PATIENTS EXHIBIT DIFFERENCES IN PHENOTYPIC RESISTANCE TO BOCEPREVIR AND TELAPREVIR IN GENOTYPE 1A REPLICON CELLS." Journal of Hepatology 56 (April 2012): S475. http://dx.doi.org/10.1016/s0168-8278(12)61210-0.
Повний текст джерелаFonseca-Coronado, S., A. Escobar-Gutierrez, K. Ruiz-Tovar, M. Y. Cruz-Rivera, P. Rivera-Osorio, M. Vazquez-Pichardo, J. C. Carpio-Pedroza, J. A. Ruiz-Pacheco, F. Cazares, and G. Vaughan. "Specific Detection of Naturally Occurring Hepatitis C Virus Mutants with Resistance to Telaprevir and Boceprevir (Protease Inhibitors) among Treatment-Naive Infected Individuals." Journal of Clinical Microbiology 50, no. 2 (November 23, 2011): 281–87. http://dx.doi.org/10.1128/jcm.05842-11.
Повний текст джерелаCento, V., V. C. Di Maio, D. Di Paolo, F. De Luca, V. Micheli, M. Tontodonati, M. C. Bellocchi, et al. "63 CORRELATION OF EARLY DETECTION OF HCV NS3-RESISTANCE AND VIROLOGICAL FAILURE IN PATIENTS TREATED WITH TRIPLE THERAPY INCLUDING TELAPREVIR OR BOCEPREVIR." Journal of Hepatology 58 (April 2013): S29. http://dx.doi.org/10.1016/s0168-8278(13)60065-3.
Повний текст джерелаZeuzem, Stefan, Richard J. Barnard, John A. Howe, Robert A. Ogert, Robert Ralston, Navdeep Boparai, Clifford A. Brass, et al. "Boceprevir Resistance-Associated Variants (Ravs) Are Observed More Frequently in HCV (GT1)-Infected Patients With Poor Response to Peginterferon Alfa-2B/Ribavirin." Gastroenterology 140, no. 5 (May 2011): S—943. http://dx.doi.org/10.1016/s0016-5085(11)63911-5.
Повний текст джерелаLarrat, Sylvie, Sophie Vallet, Sandra David-Tchouda, Alban Caporossi, Jennifer Margier, Christophe Ramière, Caroline Scholtes, et al. "Naturally Occurring Resistance-Associated Variants of Hepatitis C Virus Protease Inhibitors in Poor Responders to Pegylated Interferon-Ribavirin." Journal of Clinical Microbiology 53, no. 7 (April 29, 2015): 2195–202. http://dx.doi.org/10.1128/jcm.03633-14.
Повний текст джерелаZeuzem, S., R. J. Barnard, J. A. Howe, R. A. Ogert, R. Ralston, N. Boparai, C. A. Brass, et al. "9 BOCEPREVIR RESISTANCE-ASSOCIATED VARIANTS (RAVS) ARE OBSERVED MORE FREQUENTLY IN HCV (GT1)-INFECTED PATIENTS WITH POOR RESPONSE TO PEGINTERFERON ALFA-2B/RIBAVIRIN." Journal of Hepatology 54 (March 2011): S4—S5. http://dx.doi.org/10.1016/s0168-8278(11)60011-1.
Повний текст джерелаCurry, Stephanie, Ping Qiu та Xiao Tong. "Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN α-2b using TaqMan mismatch amplification mutation assay". Journal of Virological Methods 153, № 2 (листопад 2008): 156–62. http://dx.doi.org/10.1016/j.jviromet.2008.07.020.
Повний текст джерелаOgert, Robert A., Patricia Mendez, Janice K. Albrecht, Clifford A. Brass, Jianmin Long, John A. Howe, Robert Ralston, Richard J. Barnard, and Daria Hazuda. "Presence of Baseline Boceprevir (Boc) Resistance-Associated Variants (Ravs) Appears Not to Influence Treatment Outcomes in the Majority of Patients Following Boc/PR Treatment." Gastroenterology 140, no. 5 (May 2011): S—946. http://dx.doi.org/10.1016/s0016-5085(11)63921-8.
Повний текст джерелаGottwein, Judith M., Sanne B. Jensen, Stéphanie B. N. Serre, Lubna Ghanem, Troels K. H. Scheel, Tanja B. Jensen, Henrik Krarup, Nathalie Uzcategui, Lotte S. Mikkelsen, and Jens Bukh. "Adapted J6/JFH1-Based Hepatitis C Virus Recombinants with Genotype-Specific NS4A Show Similar Efficacies against Lead Protease Inhibitors, Alpha Interferon, and a Putative NS4A Inhibitor." Antimicrobial Agents and Chemotherapy 57, no. 12 (September 23, 2013): 6034–49. http://dx.doi.org/10.1128/aac.01176-13.
Повний текст джерелаOgert, Robert A., John A. Howe, John M. Vierling, Paul Y. Kwo, Eric J. Lawitz, Jonathan McCone, Eugene R. Schiff та ін. "Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 Trial F". Antiviral Chemistry and Chemotherapy 18, № 3 (2013): 387–97. http://dx.doi.org/10.3851/imp2549.
Повний текст джерелаHowe, John A., Ping Qiu, Robert A. Ogert, Patricia Mendez, Clifford A. Brass, Janice K. Albrecht, Robert Ralston, Richard J. Barnard, and Daria Hazuda. "Frequencies of Resistance-Associated Amino Acid Variants Detected by 454 Sequencing During Combination Treatment With Boceprevir Plus Pegintron (Peginterferon Alfa-2B)/Ribavirin in HCV (G1)-Infected Patients." Gastroenterology 140, no. 5 (May 2011): S—944. http://dx.doi.org/10.1016/s0016-5085(11)63914-0.
Повний текст джерелаYau, Alan Hoi Lun, and Eric M. Yoshida. "Hepatitis C Drugs: The End of the Pegylated Interferon Era and the Emergence of All-Oral, Interferon-Free Antiviral Regimens: A Concise Review." Canadian Journal of Gastroenterology and Hepatology 28, no. 8 (2014): 445–51. http://dx.doi.org/10.1155/2014/549624.
Повний текст джерелаHowe, J. A., P. Qiu, R. A. Ogert, P. Mendez, C. A. Brass, J. Albrecht, R. Ralston, R. J. O. Barnard, and D. Hazuda. "433 FREQUENCIES OF RESISTANCE-ASSOCIATED AMINO ACID VARIANTS DETECTED BY 454-SEQUENCING DURING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEGINTRON (PEGINTERFERON ALFA-2B)/RIBAVIRIN IN HCV (GT1)-INFECTED PATIENTS." Journal of Hepatology 54 (March 2011): S176. http://dx.doi.org/10.1016/s0168-8278(11)60435-2.
Повний текст джерелаDi Maio, V. C., D. Armenia, V. Cento, D. Di Paolo, M. Tontodonati, V. Micheli, M. C. Bellocchi, et al. "Does ultra-deep-sequencing in HCV patients treated with boceprevir/telaprevir-based therapy provide an added value in comparison to standard population-sequencing in the detection of resistance?" Digestive and Liver Disease 46 (February 2014): e47-e48. http://dx.doi.org/10.1016/j.dld.2014.01.105.
Повний текст джерелаKjellin, Midori, Terése Wesslén, Erik Löfblad, Johan Lennerstrand, and Anders Lannergård. "The effect of the first-generation HCV-protease inhibitors boceprevir and telaprevir and the relation to baseline NS3 resistance mutations in genotype 1: experience from a small Swedish cohort." Upsala Journal of Medical Sciences 123, no. 1 (January 2, 2018): 50–56. http://dx.doi.org/10.1080/03009734.2018.1441928.
Повний текст джерелаMakara, Mihály, Gábor Horváth, Judit Gervain, Alajos Pár, Ferenc Szalay, László Telegdy, István Tornai, Eszter Újhelyi, and Béla Hunyady. "Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis." Orvosi Hetilap 153, no. 10 (March 2012): 375–94. http://dx.doi.org/10.1556/oh.2012.29338.
Повний текст джерелаHowe, John A., Jianmin Long, Stuart Black, Robert Chase, Patricia McMonagle, Stephanie Curry, Seth Thompson, Mark J. DiNubile, and Anita Y. M. Howe. "Clinical Implications of Detectable Baseline Hepatitis C Virus-Genotype 1 NS3/4A-Protease Variants on the Efficacy of Boceprevir Combined With Peginterferon/Ribavirin." Open Forum Infectious Diseases 1, no. 2 (2014). http://dx.doi.org/10.1093/ofid/ofu078.
Повний текст джерела"P094: Naturally occuring cross - resistance mutation to boceprevir and telaprevir in a naive chronic hepatitis-C patient: Presentation of a case." Journal of Viral Hepatitis 22 (June 2015): 68. http://dx.doi.org/10.1111/jvh.89_12425.
Повний текст джерела